SGMO
SGMO
NASDAQ · Biotechnology

Sangamo Therapeutics Inc

$0.17
+0.01 (+7.49%)
As of Aug 16, 10:42 PM ET ·
Financial Highlights (FY 2026)
Revenue
27.90M
Net Income
-86,670,952
Gross Margin
Profit Margin
-310.8%
Rev Growth
-29.2%
D/E Ratio
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 31.5% 31.5%
Operating Margin -306.5% -275.9% -14.2% -12.4%
Profit Margin -310.8% -295.3% -12.9% -14.6%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 27.90M 39.38M 23.70M 20.49M
Gross Profit 7.47M 6.46M
Operating Income -85,509,351 -108,652,288 -3,376,071 -2,532,481
Net Income -86,670,952 -110,128,274 -3,056,252 -2,992,966
Gross Margin 31.5% 31.5%
Operating Margin -306.5% -275.9% -14.2% -12.4%
Profit Margin -310.8% -295.3% -12.9% -14.6%
Rev Growth -29.2% -29.2% +16.7% +8.2%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 0 0 61.71M 62.11M
Total Equity 96.81M 91.91M
D/E Ratio 0.64 0.68
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -82,699,933 -110,920,424 -4,785,189 -3,856,552
Free Cash Flow -2,136,953 -2,270,748